[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
IJRR Information::
For Authors::
For Reviewers::
News & Events::
Web Mail::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Hard Copy 2322-3243
Online 2345-4229
Online Submission
Now you can send your articles to IJRR office using the article submission system.



:: Volume 20, Issue 4 (10-2022) ::
Int J Radiat Res 2022, 20(4): 823-827 Back to browse issues page
Compartmental modeling and absorbed dose assessment of 188-Re-HYNIC-PSMA according to the rats’ biodistribution data
M. Hadisi , N. Vosoughi , H. Yousefnia , A. Bahrami-Samani Bahrami-Samani , S. Zolghadri , R. Bagheri
Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran , hyousefnia@aeoi.org.ir
Abstract:   (768 Views)
Background: PSMA is known as a suitable marker for imaging and targeted therapy of malignant tumors, especially prostate cancer. While; 177Lu-labeled PSMA is recognized as a promising compound for the treatment of metastatic castration-resistant prostate cancer patients, deployment of radionuclides with higher beta energy, including 188Re, can be useful for larger-sized tumors. However, the absorbed dose of the PSMA radiolabeled compound is substantial according to the considerable accumulation in the kidney. Materials and Methods: In this study; the biodistribution of 188Re-HYNIC-PSMA was studied in Wistar rats. ANACOMP software was utilized for compartmental modeling. The human absorbed dose of this new agent was assessed according to the rats’ biodistribution data using the RADAR method. Results: The highest accumulation of activity in Wistar rats’ organs were observed in the kidney. The human organs that received the highest absorbed dose were the kidneys and bladder wall with 0.69 and 0.46 mSv/MBq, respectively. Conclusion: The absorbed dose of 188Re-PSMA-617 in critical organs is comparable to the values of 177Lu-PSMA-617. 188Re-HYNIC-PSMA can be considered a safe compound for the treatment of PSMA expressing tumors.
Keywords: Compartmental modeling, absorbed dose, PSMA, 188Re.
Full-Text [PDF 658 kb]   (472 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
1. Bacich DJ, Pinto JT, Tong WP, Heston WD (2001) Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome, 12(2):117-123. [DOI:10.1007/s003350010240] [PMID]
2. El Fakiri M, Geis NM, Ayada N, Eder M, Eder AC (2021) PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers, 13(16): 3967. [DOI:10.3390/cancers13163967] [PMID] []
3. Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I (2019) A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC) Mol Imaging Biol, 21(5): 799-807. [DOI:10.1007/s11307-018-01307-0] [PMID]
4. Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, et al. (2018) Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat, 169(3): 447-455. [DOI:10.1007/s10549-018-4717-y] [PMID]
5. Heitkötter B, Steinestel K, Trautmann M, Grünewald I, Barth P, Gevensleben H, Bögemann M, et al. (2018) Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget, 9(11): 9867-9874. [DOI:10.18632/oncotarget.23984] [PMID] []
6. Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011) Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol, 24(11): 1521-9. [DOI:10.1038/modpathol.2011.112] [PMID]
7. Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, et al. (2017) Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PloS one, 12(10): e0186280. [DOI:10.1371/journal.pone.0186280] [PMID] []
8. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, et al. (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human Pathology, 40(12): 1754-1761. [DOI:10.1016/j.humpath.2009.06.003] [PMID]
9. Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S (2021) 68Ga-PSMA-11 NDA Approval: A novel and successful academic partnership. J Nucl Med, 62(2):149-155. [DOI:10.2967/jnumed.120.260455] [PMID] []
10. Rathke H, Flechsig P, Mier W, Bronzel M, Mavriopoulou E, Hohenfellner M, Giesel FL, et al. (2019) Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617. J Nucl Med, 60(6): 806-811. [DOI:10.2967/jnumed.118.218917] [PMID]
11. Sun M, Niaz MO, Nelson A, Skafida M, Niaz MJ (2020) Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus, 12(6): e8921. [DOI:10.7759/cureus.8921] [PMID] []
12. Garnuszek P, Karczmarczyk U, Maurin M, Sikora A, Zaborniak J, Pijarowska-Kruszyna J, Jaroń A, et al. (2021) PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties. Int J Mol Sci, 22(5): 2731. https://doi.org/10.3390/ijms22052731 [DOI:10.37247/PAMOL2ED.2.2021.23] [PMID] []
13. Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Published online June 16, 2021. Accessed June 16, 2021. https://bit.ly/3gwu4BO.
14. Benešová M, Bauder-Wüst U, Schäfer M, Klika KD, Mier W, Haberkorn U, Kopka K, Eder M (2016) Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem, 59(5): 1761-1775. [DOI:10.1021/acs.jmedchem.5b01210] [PMID]
15. Sharifi M, Yousefnia H, Bahrami-Samani A, Jalilian AR, Zolghadri S, Vaez-Tehrani M, Maus S (2017) Optimized Production Assessment, Compartmental Modeling and Dosimetric Evaluation of 177Lu- PSMA-617 for Clinical Trials. Int J Nucl Med Res, 4(2): 19-29. [DOI:10.15379/2408-9788.2017.04.02.01]
16. Xiaoping Xu, Jianping Zhang, Silong Hu, Simin He, Xiao Bao, Guang Ma, Jianmin Luo, Cheng J, Zhang Y (2017) 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nucl Med Biol, 48: 69-75. [DOI:10.1016/j.nucmedbio.2017.01.010] [PMID]
17. Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ (2020) Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer. Sci Rep,10(1): 4179. [DOI:10.1038/s41598-020-61129-5] [PMID] []
18. Maecke H (2005) Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop, 49: 43-72. [DOI:10.1007/3-540-26809-X_3] [PMID]
19. Edelman MJ, Clamon G, Kahn D, Magram M, Lister-James J, Line BR (2009) Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. J Thorac Oncol, 4: 1550-1554. [DOI:10.1097/JTO.0b013e3181bf1070] [PMID]
20. Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP (2005) Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med, 46(1): 121-9.
21. Karamivand M, Mohammadpour-Ghazi F, Zolghadri S, Kalantari B, Alirezapour B, Yousefnia H (2021) Characterization of 188W / 188Re generator and quality control of its eluate. JonSat, 42(4): 120-126.
22. Yousefnia H, Zolghadri S, Jalilian AR (2015) Absorbed dose assessment of 177Lu-zoledronate and 177Lu-EDTMP for human based on biodistribution data in rats. J Med Phys, 40(2): 102-108. [DOI:10.4103/0971-6203.158694] [PMID] []
23. Zolghadri S, Yousefnia H, Jalilian AR, Fazaeli Y (2015) Production, quality control, biodistribution assessment and preliminary dose evaluation of [177Lu]-tetra phenyl porphyrin complex as a possible therapeutic agent. Braz J Pharm Sci, 51(2): 339-348. [DOI:10.1590/S1984-82502015000200011]
24. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 46: 1023-1027.
25. Sharifi M, Jalilian AR, Yousefnia H, Alirezapour B, Bahrami-Samani A, Zolghadri S (2018) Production, quality control, biodistribution and imaging studies of 177Lu-PSMA-617 in breast adenocarcinoma model. Radiochim Acta, 106(6): 507-513. [DOI:10.1515/ract-2017-2874]
26. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J (2017) Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci, 64(1): 52-60. [DOI:10.1002/jmrs.227] [PMID] []
27. Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr (2019) Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front Med (Lausanne), 6: 132. [DOI:10.3389/fmed.2019.00132] [PMID] []
28. Kalidindi TM, Lee SG, Jou K, Chakraborty G, Skafida M, Tagawa ST, Bander NH, Schoder H, Bodei L, Pandit-Taskar N, Lewis JS, Larson SM, Osborne JR, Pillarsetty NVK (2021) A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging, 48(8): 2642-2651. [DOI:10.1007/s00259-020-05150-w] [PMID] []
29. Sharifi M, Yousefnia H, Zolghadri S, Bahrami-Samani A, Naderi M , Jalilian AR, Geramifar P, Beiki D (2016) Preparation and biodistribution assessment of 68Ga-DKFZ-PSMA-617 for PET prostate cancer imaging. Nucl Sci Tech, 27(6):1-9. [DOI:10.1007/s41365-016-0134-2]
30. Yousefnia H, Zolghadri S, Shanehsazzadeh S (2015) Estimated human absorbed dose of 177Lu-BPAMD based on mice data: Comparison with 177Lu-EDTMP. Appl Radiat Isot, 104: 128-135. [DOI:10.1016/j.apradiso.2015.06.033] [PMID]
31. Kurth J, Krause BJ, Hakenberg O, Schwarzenboeck S, Heuschkel M (2020) [90Y]Y-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer - Post-therapeutic kidney and bone marrow dosimetry for individualized therapy. J Nucl Med, 61(1): 190.
32. Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S (2021) Examining Absorbed Doses of Indigenously Developed 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. Cancer Biother Radiopharm, 36(3): 292-304. [DOI:10.1089/cbr.2020.3640] [PMID]
33. Rosar F, Schön N, Bohnenberger H, Bartholomä M, Stemler T, Maus S, Khreish F, et al. (2021) Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys, 8(1): 40. [DOI:10.1186/s40658-021-00385-4] [PMID] []
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hadisi M, Vosoughi N, Yousefnia H, Bahrami-Samani A B, Zolghadri S, Bagheri R. Compartmental modeling and absorbed dose assessment of 188-Re-HYNIC-PSMA according to the rats’ biodistribution data. Int J Radiat Res 2022; 20 (4) :823-827
URL: http://ijrr.com/article-1-4473-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 20, Issue 4 (10-2022) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4657